Skip to main content
      RT @drdavidliew: Which bDMARD first in PsA?

      2023 @eular_org recommendation: no preferred order. All are equal in its ey

      David Liew drdavidliew

      1 year 4 months ago
      Which bDMARD first in PsA? 2023 @eular_org recommendation: no preferred order. All are equal in its eyes #EULAR2023 @RheumNow https://t.co/6HNNamAj1J
      RT @Janetbirdope: Predictive model to predict RA status via AI , to know what goes in to model or predictions may change

      Janet Pope Janetbirdope

      1 year 4 months ago
      Predictive model to predict RA status via AI , to know what goes in to model or predictions may change. Ex use of DMARDs https://t.co/fkcEKfZWl8
      RT @bella_mehta: PsA recommendations update at #EULAR2023
      New overarching principles - should take account of safety
      @rh

      Bella Mehta bella_mehta

      1 year 4 months ago
      PsA recommendations update at #EULAR2023 New overarching principles - should take account of safety @rheumnow https://t.co/rrZ0ViFRPs
      RT @AurelieRheumo: We would think that targeted therapies would have reduced GC use in RA.

      Well, this is not really the

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      We would think that targeted therapies would have reduced GC use in RA. Well, this is not really the case. Comaprison of GC use in 1999-2008 vs. 2009-2018 52% of patients remain on GC for>3Mo after initiation & 1/3 still continues after 2 years! @RheumNow #EULAR23 POS0309 https://t.co/dDkUJFlmEm
      RT @drdavidliew: Here are the PsA drugs that have come to market in recent years
      (and what a few years it’s been)
      #EUL

      David Liew drdavidliew

      1 year 4 months ago
      Here are the PsA drugs that have come to market in recent years (and what a few years it’s been) #EULAR2023 @RheumNow https://t.co/asFsHAD21y
      RT @drdavidliew: It might not be perfect, but it’s just great to have a dynamic poster floor back #EULAR2023. The hear

      David Liew drdavidliew

      1 year 4 months ago
      It might not be perfect, but it’s just great to have a dynamic poster floor back #EULAR2023. The heartbeat of the meeting! (this was near the end on the last day - it’s been properly hectic throughout) @RheumNow https://t.co/jPGO5dylvg
      RT @bella_mehta: PsA update at #EULAR2023 new mechanisms of actions since the 2019 guidelines @RheumNow https://t.co/zai

      Bella Mehta bella_mehta

      1 year 4 months ago
      PsA update at #EULAR2023 new mechanisms of actions since the 2019 guidelines @RheumNow https://t.co/zaieEHN6sW
      RT @Janetbirdope: What is the course of clinically suspect arthralgia in CCP+ vs neg? 781 pts, 136 got RA and sl more re

      Janet Pope Janetbirdope

      1 year 4 months ago
      What is the course of clinically suspect arthralgia in CCP+ vs neg? 781 pts, 136 got RA and sl more resolved symptoms. RA developed in both groups ACPA+ develop more rapidly - if resolution, still more MRI + vs neg. #EULAR2023 POS319 @RheumNow Diff patterns of progression
      RT @Janetbirdope: #Sjogrens has a positive RCT with Dazodalibep. Well tolerated in Phase 2 RCT - Congratulations -headin

      Janet Pope Janetbirdope

      1 year 4 months ago
      #Sjogrens has a positive RCT with Dazodalibep. Well tolerated in Phase 2 RCT - Congratulations -heading to phase 3 Primary outcome positive but not 2ndary but not powered for them @RheumNow #EULAR2023 @eular_org LB0003 #SSj https://t.co/Qt0KTaNjsR
      RT @AurelieRheumo: Weather impacts outcomes in RA: myth or reality? ⛈🌦

      Larger study to date 14200 weather-matched

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      Weather impacts outcomes in RA: myth or reality? ⛈🌦 Larger study to date 14200 weather-matched PROs Mean PtP PtF PtGA scores higher in winter Few meteorological measures significantly correlated w/ PROs, but correlations are weak @RheumNow #EULAR23 POS0325 https://t.co/7AJmbLQrPW
      RT @drdavidliew: Obviously lots of real world data at #EULAR2023 on JAKi safety (cardiovascular & cancer, see ORAL S

      David Liew drdavidliew

      1 year 4 months ago
      Obviously lots of real world data at #EULAR2023 on JAKi safety (cardiovascular & cancer, see ORAL Surveillance). Real problem: many still have shorter follow-up periods. Cancer in particular takes time. It’s great to see data now, but: *longer follow-up needed* +++ @RheumNow https://t.co/YH4fZgNQjY
      RT @AurelieRheumo: REMOTRA; REMote moniToring in pReclinical Arthritis

      43pts CSA 6 Mo follow up

      Pts acceptance and usa

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      REMOTRA; REMote moniToring in pReclinical Arthritis 43pts CSA 6 Mo follow up Pts acceptance and usage decrease during time (like many other studies using apps) Composite score of PROs asso w/ risk of RA (...but VPP 12%) Digital follow up of Pre-RA is not ready for clinic yet. https://t.co/o31dVEa5xt
      RT @Yuz6Yusof: #EULAR2023 #LB0003 It is unheard of therapies that potentially can improve Sjogren patients with high sym

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2023 #LB0003 It is unheard of therapies that potentially can improve Sjogren patients with high symptoms burden. Phase 2 RCT of Dazodalibep (CD40L-i) showed ESSPRI improved vs PBO. Numerical improvement in other secondary (Fatigue). Will await results in Phase 3 @RheumNow https://t.co/0NzR83apeY
      RT @Janetbirdope: Cool way to get peg uricase tolerated in #gout. ##Rapamycin nanoparticle Rx w SEL 212 a uricase -infus

      Janet Pope Janetbirdope

      1 year 4 months ago
      Cool way to get peg uricase tolerated in #gout. ##Rapamycin nanoparticle Rx w SEL 212 a uricase -infusion reactions 3.4% - all premeds w steroids and antihistamines- some stomatitis - seemed to lower uric acid and have good tolerability LB0002 @RheumNow #EULAR2023 @eular_org https://t.co/xWzuY3Xkyw
      RT @drdavidliew: Amazing the chatter in the room for this one. The idea that a new JAKi might genuinely outperform exist

      David Liew drdavidliew

      1 year 4 months ago
      Amazing the chatter in the room for this one. The idea that a new JAKi might genuinely outperform existing JAKi in hard-to-treat RA, without safety cost, is particularly enticing. We all want to see the paper & healthy skepticism of ph2, but watch this space #EULAR2023 @RheumNow https://t.co/jEyk8zqZN8